90 research outputs found
Platinum(II)-Acyclovir Complexes: Synthesis, Antiviral and Antitumour Activity
A platinum(II) complex with the antiviral drug acyclovir was synthesized and its
antiviral and anticancer properties were investigated in comparison to those of acyclovir and
cisplatin. The platinum-acyclovir complex maintained the antiviral activity of the parent
drug acyclovir, though showing a minor efficacy on a molar basis (ID50 = 7.85 and 1.02 μΜ for platinum-acyclovir and cisplatin, respectively). As anticancer agent, the platinum-acyclovir
complex was markedly less potent than cisplatin on a mole-equivalent basis, but it
was as effective as cisplatin when equitoxic dosages were administered in vivo to P388
leukaemia-bearing mice (%T/C = 209 and 211 for platinum-acyclovir and cisplatin,
respectively). The platinum-acyclovir complex was also active against a cisplatin-resistant
subline of the P388 leukaemia (%T/C = 140), thus suggesting a different mechanism of
action. The DNA interaction properties (sequence specificity and interstrand cross-linking
ability) of platinum-acyclovir were also investigated in comparison to those of cisplatin and
[Pt(dien)Cl]+, an antitumour-inactive platinum-triamine compound. The results of this study
point to a potential new drug endowed, at the same time, with antiviral and anticancer
activity and characterized by DNA interaction properties different from those of cisplatin
Water-Soluble Ruthenium(III)-Dimethyl Sulfoxide Complexes: Chemical Behaviour and Pharmaceutical Properties
In this paper we report a review of the results obtained in the last few years by our
group in the development of ruthenium(III) complexes characterized by the presence of
sulfoxide ligands and endowed with antitumor properties. In particular, we will focus on
ruthenates of general formula Na[trans-RuCl4(R1R2SO)(L)], where R1R2SO =
dimethylsulfoxide (DMSO) or tetramethylenesulfoxide (TMSO) and L = nitrogen donor
ligand. The chemical behavior of these complexes has been studied by means of
spectroscopic techniques both in slightly acidic distilled water and in phosphate buffered
solution at physiological pH. The influence of biological reductants on the chemical
behavior is also described. The antitumor properties have been investigated on a number
of experimental tumors. Out of the effects observed, notheworthy appears the capability
of the tested ruthenates to control the metastatic dissemination of solid metastasizing
tumors. The analysis of the antimetastatic action, made in particular on the MCa
mammary carcinoma of CBA mouse, has demonstrated a therapeutic value for these
complexes which are able to significantly prolong the survival time of the treated
animals. The antimetastatic effect is not attributable to a specific cytotoxicity for
metastatic tumor cells although in vitro experiments on pBR322 double stranded DNA
has shown that the test ruthenates bind to the macromolecule, causing breaks
corresponding to almost all bases, except than thymine, and are able to cause interstrand
bonds, depending on the nature of the complex being tested, some of which results active
as cisplatin itself
Novel antiproliferative biphenyl nicotinamide: NMR metabolomic study of its effect on the MCF-7 cell in comparison with cisplatin and vinblastine
A 1H-NMR-based metabolomic study was performed on MCF-7 cell lines treated with a novel nicotinamide derivative (DT-8) in comparison with two drugs characterized by a well-established mechanism of action, namely the DNA-metalating drug cisplatin (cis-diamminedichloridoplatinum(II), CDDP) and the antimitotic drug vinblastine (vinblastine, VIN). The effects of the three compounds, each one at the concentration corresponding to the IC50 value, were investigated, with respect to the controls (K), by the 1H-NMR of cells lysates and multivariate analysis (MVA) of the spectroscopic data. Relevant differences were found in the metabolic profiles of the different treatments with respect to the controls. A large overlap of the metabolic profiles in DT-8 vs. K and VIN vs. K suggests a similar biological response and mechanism of action, significantly diverse with respect to CDDP. On the other hand, DT8 seems to act by disorganizing the mitotic spindle and ultimately blocking the cell division, through a mechanism implying methionine depletion and/or S-adenosylmethionine (SAM) limitation
Ruthenium polypyridyl complexes and their modes of interaction with DNA : is there a correlation between these interactions and the antitumor activity of the compounds?
Various interaction modes between a group of six ruthenium polypyridyl complexes and DNA have been studied using a number of spectroscopic techniques. Five mononuclear species were selected with formula [Ru(tpy) L1L2](2-n)?, and one closely related dinuclear cation of formula [{Ru(apy)(tpy)}2{l-H2N(CH2)6NH2}]4?. The ligand tpy is 2,20:60,200-terpyridine and the ligand L1 is a bidentate ligand, namely, apy (2,20-azobispyridine), 2-phenylazopyridine, or 2-phenylpyridinylmethylene amine. The ligand L2 is a labile monodentate ligand, being Cl-, H2O, or CH3CN. All six species containing a labile L2 were found to be able to coordinate to the DNA model base 9-ethylguanine by 1H NMR and mass spectrometry. The dinuclear cationic species, which has no positions available for coordination to a DNA base, was studied for comparison purposes. The interactions between a selection of four representative complexes and calf-thymus DNA were studied by circular and linear dichroism. To explore a possible relation between DNA-binding ability and toxicity, all compounds were screened for anticancer activity in a variety of cancer cell lines, showing in some cases an activity which is comparable to that of cisplatin. Comparison of the details of the compound structures, their DNA binding, and their toxicity allows the exploration of structure–activity relationships that might be used to guide optimization of the activity of agents of this class of compounds
Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
NAMI-A is a ruthenium-based compound with selective anti-metastasis activity in experimental models of solid tumours. We studied whether this activity was dependent on anti-angiogenic ability of NAMI-A. We thus investigated its in vitro effects on endothelial cell functions necessary for angiogenesis to develop, as well as its in vivo effects in the chick embryo chorioallantoic membrane model. Endothelial cell proliferation, chemotaxis, and secretion of the matrix-degrading enzyme metalloproteinase-2 were inhibited by NAMI-A in a dose-dependent manner, and without morphologic signs of cell apoptosis or necrosis. Lastly, NAMI-A displayed a dose-dependent in vivo anti-angiogenic activity in the chorioallantoic membrane model. These data suggest that the anti-angiogenic activity of NAMI-A can contribute to its anti-metastatic efficacy in mice bearing malignant solid tumours
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal–organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.National Cancer Institute (U.S.) (CA034992
- …